Disease Insight Book

Understand market dynamics and unmet needs

Whether you’re evaluating a new asset, entering a competitive market, or building a launch strategy, success depends on your ability to master the therapy area landscape. We create comprehensive disease landscape that consolidates all critical information about a specific disease. We provide deep, structured, and insight-rich therapy area research to power smarter drug development, commercialization, and investment decisions. Our therapy area research covers the full landscape

Disease Overview & Epidemiology Prevalence, incidence, burden of disease, diagnostic pathways, subpopulations
Treatment Landscape & Standard of Care Current therapies, unmet needs, line of therapy, treatment algorithms
Pipeline & Clinical Trial Intelligence Competitive pipeline, trial design trends, MoAs, innovation hotspots
Key Opinion Leaders & Guidelines KOL mapping, guideline shifts, professional society influence
Market Access & Reimbursement Landscape HTA decisions, payer drivers, pricing benchmarks, access barriers
SWOT & Opportunity Mapping Tailored insights to guide BD, R&D prioritization, and strategic planning

Current Guideline Recommendations

Current Treatment Options by Patient Segments​

New Treatment Options by Patient Segments in Future​​

Emergence of New PatientSegments in Future​​

Benchmark Assessment

Current and Future SoCby Patient Segments​

Time of Impact fromCompetition

Impact on Client’s Product X​

Segments of Impact​from Competition

Can Product X remain/be an SoC in the Future?

Answers to Key Questions​

  • Is Product X better than current SoCs?
  • Is there any better treatment option than Product X likely in the future?
  • How are the new treatment options better than Product X, if any?
  • What is the future launch timing of key treatment options?
  • How is the competitor’s development strategy impacting Product X?

Can Product X remain/be an SoC in the Future?

Continuous Tracking Insightful and Actionable

Systematic Analysis in Health Economics

Quantify the economic value of new therapies through publication research

We provide systematic analysis in health economics to support pricing, reimbursement, and investment decisions with transparent, evidence-based frameworks. Our analysis focuses on evaluating cost-effectiveness, budget impact, or value-for-money of a health intervention.

We deliver structured, high-quality outputs that may include

Systematic Literature Reviews (SLRs) Cost-effectiveness, utility values, QALYs
Resource use, hospitalization, AE rates
Real-world evidence (RWE) inclusion
Economic Evaluation Cost-effectiveness analysis (CEA)
Cost-utility analysis (CUA)
Budget impact models (BIM)
Willingness-to-pay thresholds and ICER calculations
Global Adaptation Regulated market pricing and access perspectives

Common Economic Evaluation Types Covered​​

  1. CEA/CUA: Cost-effectiveness Analysis/Cost-utility Analysis​
  2. BIA: Budget Impact Analysis​
  3. CBA: Cost-benefit Analysis

Screening and ShortlistingStudies

Includes economic evaluations from publications and key institutions​

Data Capture: Key Parameters Covered​

Indication​

Intervention & Comparator​

Study Design​

Data Collection Method​

Models Used for Analysis​​

Time Horizon and Discounting​

Outcome Measures​​

Cost Calculation Perspective

Sensitivity Analysis​​

Comparison of Economic Evaluation methods and results between products, countries, institutions, etc.​

Summarization and Insights​​

Healthcare/Payer Perspective

Societal Perspective

Healthcare/Payer + Societal Perspective

Healthcare/Payer + Employer Perspective

Employer Perspective

An important input for pricing and reimbursement decisions